You are here

Article Text

Article menu

Download PDFPDF

Cerebrovascular disease
Research paper
Candidate-gene analysis of white matter hyperintensities on neuroimaging
  1. Theresa Tran1,2,
  2. Ioana Cotlarciuc1,
  3. Sunaina Yadav2,
  4. Nazeeha Hasan2,
  5. Paul Bentley2,
  6. Christopher Levi3,
  7. Bradford B Worrall4,
  8. James F Meschia5,
  9. Natalia Rost6,
  10. Pankaj Sharma1,2
  1. 1Institute of Cardiovascular Research, Royal Holloway University of London (ICR2UL) and Ashford & St Peters NHS Foundation Trust, London, UK
  2. 2Imperial College Cerebrovascular Research Unit (ICCRU), Imperial College London, London, UK
  3. 3Department of Neurology, John Hunter Hospital, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
  4. 4Departments of Neurology and Public Health Sciences, University of Virginia Health System, Charlottesville, Virginia, USA
  5. 5Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA
  6. 6Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Professor Pankaj Sharma, Institute of Cardiovascular Research, Royal Holloway University of London, Egham, TW20 OEX, UK; pankaj.sharma{at}rhul.ac.uk

Abstract

Background White matter hyperintensities (WMH) are a common radiographic finding and may be a useful endophenotype for small vessel diseases. Given high heritability of WMH, we hypothesised that certain genotypes may predispose individuals to these lesions and consequently, to an increased risk of stroke, dementia and death. We performed a meta-analysis of studies investigating candidate genes and WMH to elucidate the genetic susceptibility to WMH and tested associated variants in a new independent WMH cohort. We assessed a causal relationship of WMH to methylene tetrahydrofolate reductase (MTHFR).

Methods Database searches through March 2014 were undertaken and studies investigating candidate genes in WMH were assessed. Associated variants were tested in a new independent ischaemic cohort of 1202 WMH patients. Mendelian randomization was undertaken to assess a causal relationship between WMH and MTHFR.

Results We identified 43 case-control studies interrogating eight polymorphisms in seven genes covering 6,314 WMH cases and 15,461 controls. Fixed-effects meta-analysis found that the C-allele containing genotypes of the aldosterone synthase CYP11B2 T(−344)C gene polymorphism were associated with a decreased risk of WMH (OR=0.61; 95% CI, 0.44 to 0.84; p=0.003). Using mendelian randomisation the association among MTHFR C677T, homocysteine levels and WMH, approached, but did not reach, significance (expected OR=1.75; 95% CI, 0.90−3.41; observed OR=1.68; 95% CI, 0.97−2.94). Neither CYP11B2 T(−344)C nor MTHFR C677T were significantly associated when tested in a new independent cohort of 1202 patients with WMH.

Conclusions There is a genetic basis to WMH but anonymous genome wide and exome studies are more likely to provide novel loci of interest.

  • STROKE
  • GENETICS

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/jnnp-2014-309685

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    White matter hyperintensities (WMH) are defined as diffuse white matter abnormalities detected on T2-weighted or fluid attenuated inversion recovery (FLAIR) MRI and appearing as regions of low attenuation on brain CT scans.1 They are a common radiological finding, particularly in older individuals, with a reported prevalence of up to 95%.2 ,3 These lesions, of presumed vascular origin, may represent an endophenotype for small cerebral vessel diseases such as stroke and dementia; thus, WMH could be used in early diagnosis and guided management of these conditions.4 WMH has consistently been associated with increasing age and hypertension,5 as well as smoking,6 previous stroke7 or TIA,8 and elevated homocysteine (Hcy) levels.9 ,10 Studies have reported high heritability estimates ranging between 55% and 71%,11–13 implying a significant genetic component to WMH development.

    To date, a single WMH GWAS has been published by the CHARGE consortium14 that identified six single nucleotide polymorphisms (SNPs) in a novel locus on chromosome 17q25 associated with WMH burden in stroke-free participants.14 The most significantly associated SNP on 17q25 was rs3744028 with a reported p value of 1.0×10−9 after adjustment for hypertension.14 This association between the 17q25 locus and WMH has recently been tested in a cohort of ischaemic patients with stroke, where it has replicated in association with WMH volume but not lacunar stroke status.15 The latter may suggest that these two diseases have distinct pathogeneses of cerebral microangiopathy. Rs3744028 was again found to be significantly associated with increased WMH burden (effect size=0.12; SE=0.04; p=0.003), although this SNP was not the most significantly associated in this study population (rs9894383; effect size=0.13; SE=0.04; p=0.0006).

    Several statistically underpowered small candidate gene studies on WMH have been published, but the results remain invalid due to low power. By consolidating data from these smaller studies, a literature-based meta-analysis is considered to be the next best way to increase power and find a true genetic risk association. We conducted a comprehensive meta-analysis of all case–control studies investigating candidate genes in WMH, tested our findings in a new independent WMH cohort and sought to identify a causal relationship with methylene tetrahydrofolate reductase (MTHFR).

    Methods

    A comprehensive search strategy in electronic databases (PubMed, Google Scholar, Embase) was undertaken using a range of search terms for WMH (leukoaraiosis, white matter hyperintensities, white matter lesions, white matter disease, age-related white matter changes, homocysteine, hyperhomocysteinaemia) in combination with the Boolean operator AND/OR (genetics, genotype, genes or polymorphism). Further searches were conducted for each gene identified, using specific gene names combined with the WMH search terms. Additional studies were found by hand searching reference lists of relevant papers. For duplicate papers, the largest cohort was selected. A variety of different methods were utilised to quantify WMH levels or volumes, but in general visual rating scales were more commonly used than automated programmes. Most papers reported genotype frequencies within the Hardy-Weinberg equilibrium. Our study complied with PRISMA guidelines.

    Study selection

    Inclusion criteria were: (1) case–control studies where WMH was reported as a grade on a standardised scale or as a volume, (2) WMH was objectively confirmed by MRI or CT brain scans, (3) genotype frequency was reported for WMH cases and controls. Studies were excluded if they did not explicitly distinguish WMH from other brain lesions such as lacunes and microinfarcts. For the Mendelian randomisation part of this study, additional selection was based on plasma Hcy levels for cases and controls in the studies of participants of European descent reporting SDs associated with mean Hcy levels.

    Data extraction

    Some studies quantified WMH grade on a standardised scale and presented this as dichotomous data, so for each genotype the number of participants in the highest and lowest WMH grade groups was extracted. Where studies subdivided WMH into two categories: deep (or subcortical) WMH and periventricular WMH, without providing data for WMH as a whole, data for the deep WMH was analysed. In cases where the scale cut-off could be chosen, the upper grade group included Fazekas scale 2 or 3 or equivalent.16 For continuous WMH grade data, the mean grade and SD for each genotype were taken, and for studies presenting WMH data as a volume, we extracted the mean volume and SD for each genotype.

    Data analysis for meta-analysis

    Data were analysed using Review Manager V.5.2. Using a Mantel-Haenszel statistical method, a pooled OR and 95% CI were calculated for each SNP-WMH association. Statistical significance was set at p<0.05. Where significant heterogeneity was detected, a random-effects analysis model was utilised in order to account for this interstudy heterogeneity. In all other cases, a fixed effects model was used. Heterogeneity was assessed with an I2 test for each meta-analysis (significance set at p<0.10) and an iterative analysis was performed where significant heterogeneity was found. Publication bias was assessed with Funnel plots and by performing Egger's regression analysis (two-tailed tests) using Comprehensive Meta-Analysis V.2.0 (CMA).

    Data analysis for Mendelian randomisation

    Mendelian randomisation allows the testing of a causal effect of observed data in the presence of confounding factors. Review Manager was used to calculate an OR and 95% CI for MTHFR-WMH grade association using the TT vs CC model so as to be in keeping with the model used by Casas et al17 who report a weighted mean difference in the Hcy level between TT and CC-genotype to be 1.93 μmol/L in their meta-analysis. A pooled mean difference in Hcy levels between cases with WMH and controls was calculated and then converted into a corresponding OR of WMH for that specific increase in Hcy level using CMA software. The expected OR was then calculated using the following formula:17Embedded Image where X=the OR of risk of WMH for a Z μmol/L increase in plasma Hcy levels.

    And Y=the mean difference in the Hcy level (μmol/L) between TT and CC-genotype participants.

    To calculate the 95% CI for the expected OR, we took the natural log of this number to determine the logged OR. The 95% CI for this logged OR is calculated by taking 1.96×SE on either side of this logged OR.18 The SE is taken as the square root of the sum of the reciprocals of the number of cases and controls. The exponential function in Excel was used to convert the upper and lower CI limits into the 95% CI limits for the original OR.

    Replication of the associated genetic variants

    Any associated genetic variants were tested in a cohort of 1202 ischaemic stroke cases of European ancestry with genome-wide genotyping available (‘MGH,’ ‘ISGS,’ ‘ASGS,’ ‘SWISS’ cohorts) that was previously used to replicate chromosome 17q25 locus association with WMH.15 In this cohort, WMH volume (WMHv) was measured using a previously validated, semiautomated volumetric method (facilitated by MRIcro, University of Nottingham School of Psychology, Nottingham, UK; http://www.mricro.com).19 For this analysis, MRI scans obtained from a 1.5 T scanner were converted from DICOM into Analyse format, and the contiguous, supratentorial axial T2 FLAIR sequences were cross-referenced with diffusion-weighted images (DWI) and examined to exclude hyperintensities that represent oedema, acute ischaemia or chronic infarcts. WMHs were manually outlined as regions of interest, and their intersections with automatically derived intensity thresholds were manually examined and touched up by a trained reader. The total WMHv was calculated by doubling the measurement from the hemisphere unaffected by stroke, or by adding bilateral WMHv values in participants with infratentorial DWI lesions. To control for variation in head size, the intracranial area (ICA) was calculated from two middle sagittal T1 slices and used to normalise WMHv by multiplying it by the individual-to-the-mean ICA ratio.20 ,21 Specific study characteristics and genotyping information of this cohort are previously described.15

    Results

    Our initial search identified 1248 studies with 20 additional records from references of relevant articles. Removal of duplicates and matches to our predefined inclusion and exclusion criteria resulted in 43 studies which had available data for meta-analysis interrogating nine polymorphisms in 10 different genes (figure 1). The majority used MRI to assess WMH in (mostly Caucasian) participants aged between 60 and 80 years. Most of the genes studied were involved in the renin-angiotensin-aldosterone system (ACE, angiotensinogen (AGT), angiotensin II receptor 1, aldosterone synthase). The other identified genes had roles in Hcy levels (MTHFR), antiatherosclerosis (paraoxonase 1) and cholesterol regulation (apolipoprotein E). Other gene polymorphisms studied were brain-derived neurotrophic factor/Val66Met22 and nitric oxide synthase 3/G894T,23 ,24 but some studies had yet to be replicated22 and others did not have data available for meta-analysis24 (table 1).

    View this table:
    Table 1

    Summary table demonstrating each gene, polymorphism, model used, number of cases and controls and resulting OR, CI and p values

    Figure 1
    Figure 1

    PRISMA flow chart demonstrating the search strategy.

    MTHFR677 cytosine/thymine (TT vs CT/CC)

    Six studies investigated the association between the MTHFR C677T polymorphism (TT vs CT/CC) and WMH (n=4002).25–30 Five studies (n=2988) assessed the genotype difference between the lower and upper WMH grade groups25 ,26 ,28–30 (figure 2A) and one study (n=1014) compared the mean WMH volume between different genotypes27 (figure 2B). A fixed-effects meta-analysis demonstrated a trend of increased risk burden of WMH with MTHFR TT compared to the CT/CC genotype (OR=1.19; 95% CI 0.95 to 1.51; p=0.14; I²=28%; p=0.24) when the totality of data was plotted (see figure 2). Only one study measured the WMH volume, thus limiting further analysis (standardised mean difference=−0.09; 95% CI −0.29 to 0.11; p=0.37).

    Figure 2
    Figure 2

    Meta-analysis, forest plot and pooled OR of risk from studies investigating the association between WMH and methylene tetrahydrofolate reductase, MTHFR (TT vs CT/CC, recessive model). (A) Graded WMH, dichotomous data (B) WMH volume. MTHFR, methylene tetrahydrofolate reductase; WMH, white matter hyperintensities.

    Aldosterone synthase CYP11B2T(-344)C (CC/CT vs TT)

    Two studies (n=1153) evaluated the association between the aldosterone synthase CYP11B2T(-344)C polymorphism and dichotomous graded WMH, and the fixed-effects meta-analysis demonstrated that the C-allele-containing genotypes were at a reduced risk of white matter lesions (OR=0.61; 95% CI 0.44 to 0.84; p=0.003; I²=0%; p=0.70).31 ,32

    Apolipoprotein E (ε4 allele-containing genotypes vs others)

    There were 31 studies/substudies that investigated the association between apoE (ε4 allele-containing genotypes vs other genotypes) and WMH (n=11 270).29 ,33–57 Twenty-two of these studies (n=7622) assessed the genotype difference between the lower and upper WMH grade groups,29 ,33–41 ,50–58 three studies (n=187) compared the mean WMH grade42–44 and six studies (n=3461) compared the mean WMH volume between different genotype groups.45–49

    The fixed-effects meta-analysis demonstrated no association between apoE ε4-allele carriage status and having severe WMH on neuroimaging (WMH grade, dichotomous data, OR=0.98; 95% CI 0.87 to 1.11; p=0.78; I²=5%; p=0.39). Within participants with WMH, there was no significant predominance of the ε4 allele-containing genotypes (WMH grade, continuous data, pooled standardised mean difference=0.29; 95% CI −0.03 to 0.61; p=0.07; I²=0%; p=0.87; WMH volume, pooled standardised mean difference=0.06; 95% CI −0.02 to 0.14; p=0.14; I²=47%; p=0.09).

    ApoE/ε2 allele-containing genotypes vs others

    Three studies (n=817) evaluated the risk of WMH in apolipoprotein E ε2-containg genotypes compared to other apolipoprotein E genotypes38 ,41 ,52 and a random-effects meta-analysis reported no significant association (OR=1.42; 95% CI 0.46 to 4.43; p=0.54) but significant heterogeneity was detected (I2=84; p=0.002). Iterative analysis revealed that the source of inter-study heterogeneity was attributable to Smith 2004,52 the exclusion of which resulted in pooled OR=2.59; 95% CI 1.60 to 4.19; p=0.0001; I2=0%; p=0.92.

    ACE (DD vs ID/II)

    Nine studies/substudies evaluated the association between ACE (DD vs ID/II model) and WMH (n=2615).29 ,31 ,33 ,59–63 Eight studies (n=2121) assessed the genotype difference between the lower and upper WMH grade groups29 ,31 ,33 ,60–63 and 1 study (n=494) compared the mean WMH volume between different genotypes.59 The random-effects meta-analysis suggested no increased risk of WMH with ACE DD-genotype compared to those with ID or II genotype (OR=1.46; 95% CI 0.92 to 2.31; p=0.11), but there was substantial heterogeneity detected between studies (I²=67%; p=0.004). No one study contributed to the heterogeneity as determined by iterative analysis. One study assessed WMH volume and also reported non-significance (standardised mean difference=−0.07; 95% CI −0.27 to 0.13; p=0.48).

    Angiotensinogen Met235Thr (TT/MT vs MM)

    Four studies (n=1134) evaluated the association between AGT M235T (TT/MT vs MM model) and dichotomous graded WMH and fixed-effects meta-analysis found no association between them (OR=1.12; 95% CI 0.84 to 1.50; p=0.77; I²=0%; p=0.44).31 ,60 ,61 ,64

    Angiotensin II receptor 1 A1166C (CC vs AC/AA)

    Two studies (n=459) investigated whether the angiotensin II receptor 1 (AGTR1) A1166C polymorphism was associated with dichotomous WMH grade. Using the dominant model (CC vs AC/AA) and a fixed-effects analysis, our meta-analysis found no association (OR=1.23; 95% CI 0.59 to 2.54; p=0.58; I2=23%; p=0.26).31 ,60

    Paraoxonase 1 L55M (LL/LM vs MM)

    Two studies (n=343) evaluated the association between the paraoxonase 1 (PON1) gene and dichotomous graded WMH and fixed-effects meta-analysis found no association between them (OR=1.42; 95% CI 0.61 to 3.28; p=0.41; I²=0%; p=0.33).65 ,66

    Mendelian randomisation

    Ninety-seven studies and five additional records were identified in the search for papers investigating the difference in plasma Hcy levels between WMH cases and controls. After 21 duplicate records were removed, the remaining 81 were screened and 77 were excluded according to the predefined inclusion and exclusion criteria.

    Ethnic differences in plasma Hcy levels are well documented with East Asians consistently reported to have significantly lower Hcy levels compared to Caucasians67–70 (table 2). Given these ethnic disparities, we considered it appropriate to exclude studies of East Asian (ie, Japanese, Korean) participants from the Mendelian randomisation, as the majority of studies were conducted in participants of European descent.

    View this table:
    Table 2

    Ethnic differences in plasma homocysteine level between East Asian and Caucasian participants

    The remaining four studies covering 745 Caucasian participants were meta-analysed and a comparison of WMH cases vs controls found a pooled mean difference in plasma Hcy levels of 3.71 μmol/L (95% CI 2.79 to 4.63; p<0.00001; I2=0%) (figure 3). CMA V.2.0 software was used to calculate the corresponding pooled OR of risk of WMH for this mean difference in Hcy levels using a fixed effects analysis model, OR=2.93 (95% CI 2.18 to 3.94).

    Figure 3
    Figure 3

    Meta-analysis of studies investigating the mean difference in homocysteine levels (µmol/L) between white matter hyperintensities (WMH) cases and controls.

    In a meta-analysis of 42 studies, we had previously examined the effect of MTHFR on plasma Hcy levels in healthy participants (n=15 635) and reported the weighted mean difference in the Hcy level between TT and CC-genotype to be 1.93 μmol/L (95% CI 1.38 to 2.47; p<0.0001).17 Using these three pieces of data, the expected OR was calculated using the following formula:Embedded Image

    where:

    • 2.93 is the OR of risk of WMH for a 3.709 μmol/L increase in plasma Hcy levels,

    • 1.93 is the mean difference in the Hcy level (μmol/L) between TT and CC-genotype participants.

    To calculate the 95% CI for the expected OR of 1.75, we took the natural log of 1.75 to get the logged OR of 0.56. The 95% CI for this logged OR was −0.108 to 1.227 and was calculated by taking 1.96×SE on either side of 0.56.18 The SE was 0.34, which was calculated as the square root of the sum of the reciprocals of the number of cases and controls. Using the exponential function in excel, these limits were converted into the 95% CI limits for the original OR of 1.75 giving EXP (−0.108)=0.897 to EXP (1.227)=3.412. From our meta-analysis of two studies investigating the association between MTHFR (TT vs CC) and WMH grade, the observed OR for WMH was 1.68 (95% CI 0.97 to 2.94, p=0.07). Despite the results not reaching statistical significance, the similarity between the expected and observed ORs supports a likely causal relationship between MTHFR and WMH.

    Replication of associated genetic variants

    We examined the association between CYP11B2T(-344)C and MTHFR C677T polymorphisms and WMH quantified on the MRI using a validated, semiautomated volumetric protocol in an independent cohort of 1202 ischaemic stroke cases with WMH. There was no association between either polymorphism and the WMH volume in this cohort (CYP11B2T(-344)C, P=0.5755; MTHFR C677T, P=0.68).

    Discussion

    In this largest study to date of candidate genes in WMH burden, we interrogated 6253 WMH cases and 15 239 controls for eight polymorphisms in seven genes (APO E/ε4 and ε2, ACE insertion/deletion, MTHFR C677T, AGT M235T, AGTR1 A1166C, CYP11B2 T344C, PON1 L55M). Our analysis demonstrated a likely genetic effect for ischaemic white matter disease, with an apparent inverse association between CYP11B2 and WMH. A trend for positive association between MTHFR and WMH severity could not be completely interrogated, given the relatively small sample size of the available studies as compared to other well-powered genetic studies on stroke.

    The MTHFR gene is involved in plasma Hcy levels and may contribute to endothelial dysfunction, which is one of the suggested mechanisms behind WMH.71 While the association between the MTHFR TT-genotype and WMH fell shy of statistical significance, the totality of the data suggested a trend for association. The Mendelian randomisation approach allowed us to investigate any potential relationship between MTHFR and WMH in more depth and evaluate for potential causality. The particular strengths of this method are that confounding factors are equally distributed among genotypes, which facilitates causality to be tested in their presence, whereas measurement error bias, reverse causality and selection biases are largely overcome.72 Using this approach yielded similar values for the expected and observed OR, and there was considerable overlap of their 95% CIs. Given that the two values are derived from meta-analyses of the different study types (genetic association vs observational)—either of which is prone to a different source of bias—might be suggestive of a causal association between Hcy and WMH burden.73 However, this analysis was insufficiently powered, and future studies using an adequate sample size may prove more conclusive.

    A number of study limitations need to be documented. Publication bias is always a concern in meta-analysis. However, funnel plots were produced for each gene-WMH association and Egger's regression analysis (two-tailed test) was performed to assess publication bias. Given that the majority of included studies reported non-significant results, substantial publication bias is considered unlikely, although it can never be completely excluded. Further, of the 78 studies investigating the association of candidate genes and WMH, just under half did not have usable data for meta-analysis. It may be that the authors of these papers did not consider the data to be interesting enough to report (selective outcome reporting). The vast majority of these studies found no association and their inclusion would have strengthened our finding of no relationship between WMH and any of the studied gene polymorphisms. Some studies reported data according to a genetic model they had chosen rather than reporting event rates for each genotype separately, which limited our ability to incorporate their studies into other genetic models. There was considerable variation in WMH measurement methods used between studies, which introduces methodological heterogeneity. Assessing WMH using visual rating scales can be subjective and observer dependent,3 although most papers reported good inter-rater agreement. The inclusion of CT and MRI studies adds another source of interstudy heterogeneity. CT has been shown to be less sensitive at detecting WMH and its use may result in an underestimation of the true WMH load within those studies. However, removal of these studies did not lead to a substantial change in the pooled OR; thus, we considered it appropriate to include them. Finally, results could be confounded by failure to adjust for age, intracranial volume and vascular risk factors in all studies. Additionally, consideration ought to be given in analyses to the known WMH risk factors since genes may be exerting their effect through these factors. The variable disease status of the study populations could have introduced heterogeneity into our analysis. For example, six studies in our APO E4 analysis were conducted in participants with probable or pathologically confirmed Alzheimer's disease.74 ,75 Combining these studies with those of asymptomatic participants could have confounded our results. Finally, a number of covariates which we are not able to assess because of a lack of complete data sets may influence our final results.

    Despite undertaking, to the best of our knowledge, the largest meta-analysis to date along with studying a new independent WMH cohort, the genetics of this condition remains unclear. Future genetic studies not using an a priori hypothesis may shed further light on this field.

    Acknowledgments

    PS is a former Department of Health (UK) Senior Fellow. PB holds a Department of Health (UK) Senior Fellowship.

    References

    1. ↵
      1. O'Sullivan M
      . Leukoaraiosis. Pract Neurol 2008;8:26–38. doi:10.1136/jnnp.2007.139428
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. De Leeuw F,
      2. De Groot J,
      3. Achten E, et al
      . Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. the rotterdam scan study. J Neurol Neurosurg Psychiatry 2001;70:9–14. doi:10.1136/jnnp.70.1.9
      OpenUrlAbstract/FREE Full Text
    3. ↵
      1. Grueter BE,
      2. Schulz UG
      . Age-related cerebral white matter disease (leukoaraiosis): a review. Postgrad Med J 2012;88:79–87. doi:10.1136/postgradmedj-2011-130307
      OpenUrlAbstract/FREE Full Text
    4. ↵
      1. Assareh A,
      2. Mather KA,
      3. Schofield PR, et al
      . The genetics of white matter lesions. CNS Neurosci Ther 2011;17:525–40. doi:10.1111/j.1755-5949.2010.00181.x
      OpenUrlCrossRefPubMed
    5. ↵
      1. Dufouil C,
      2. de Kersaint–Gilly A,
      3. Besancon V, et al
      . Longitudinal study of blood pressure and white matter hyperintensities the EVA MRI cohort. Neurology 2001;56:921–6. doi:10.1212/WNL.56.7.921
      OpenUrlCrossRefPubMed
    6. ↵
      1. Jeerakathil T,
      2. Wolf PA,
      3. Beiser A, et al
      . Stroke risk profile predicts white matter hyperintensity volume the framingham study. Stroke 2004;35:1857–61. doi:10.1161/01.STR.0000135226.53499.85
      OpenUrlAbstract/FREE Full Text
    7. ↵
      1. Debette S,
      2. Markus H
      . The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ 2010;341:c3666. doi:10.1136/bmj.c3666
      OpenUrlAbstract/FREE Full Text
    8. ↵
      1. Henon H,
      2. Godefroy O,
      3. Lucas C, et al
      . Risk factors and leukoaraiosis in stroke patients. Acta Neurol Scand 1996;94:137–44. doi:10.1111/j.1600-0404.1996.tb07044.x
      OpenUrlPubMed
    9. ↵
      1. Wright CB,
      2. Paik MC,
      3. Brown TR, et al
      . Total homocysteine is associated with white matter hyperintensity volume the northern manhattan study. Stroke 2005;36:1207–11. doi:10.1161/01.STR.0000165923.02318.22
      OpenUrlAbstract/FREE Full Text
    10. ↵
      1. Rost NS,
      2. Rahman R,
      3. Sonni S, et al
      . Determinants of white matter hyperintensity volume in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2010;19:230–5. doi:10.1016/j.jstrokecerebrovasdis.2009.05.007
      OpenUrlCrossRefPubMed
    11. ↵
      1. Atwood LD,
      2. Wolf PA,
      3. Heard-Costa NL, et al
      . Genetic variation in white matter hyperintensity volume in the framingham study. Stroke 2004;35:1609–13. doi:10.1161/01.STR.0000129643.77045.10
      OpenUrlAbstract/FREE Full Text
    12. ↵
      1. Carmelli D,
      2. DeCarli C,
      3. Swan GE, et al
      . Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998;29:1177–81. doi:10.1161/01.STR.29.6.1177
      OpenUrlAbstract/FREE Full Text
    13. ↵
      1. Turner ST,
      2. Jack CR,
      3. Fornage M, et al
      . Heritability of leukoaraiosis in hypertensive sibships. Hypertension 2004;43:483–7. doi:10.1161/01.HYP.0000112303.26158.92
      OpenUrlCrossRef
    14. ↵
      1. Fornage M,
      2. Debette S,
      3. Bis JC, et al
      . Genome-wide association studies of cerebral white matter lesion burden. Ann Neurol 2011;69:928–39. doi:10.1002/ana.22403
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      1. Adib-Samii P,
      2. Rost N,
      3. Traylor M, et al
      . 17q25 locus is associated with white matter hyperintensity volume in ischemic stroke, but not with lacunar stroke status. Stroke 2013;44:1609–15. doi:10.1161/STROKEAHA.113.679936
      OpenUrlAbstract/FREE Full Text
    16. ↵
      1. Paternoster L,
      2. Chen W,
      3. Sudlow CL
      . Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. Stroke 2009;40:2020–6. doi:10.1161/STROKEAHA.108.542050
      OpenUrlAbstract/FREE Full Text
    17. ↵
      1. Casas JP,
      2. Bautista LE,
      3. Smeeth L, et al
      . Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. Lancet 2005;365:224–32. doi:10.1016/S0140-6736(05)70152-5
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      1. Bland JM,
      2. Altman DG
      . Statistics notes: the odds ratio. BMJ 2000;320:1468. doi:10.1136/bmj.320.7247.1468
      OpenUrlFREE Full Text
    19. ↵
      1. Rost NS,
      2. Rahman RM,
      3. Biffi A, et al
      . White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology 2010;75:1670–7. doi:10.1212/WNL.0b013e3181fc279a
      OpenUrlCrossRefPubMed
    20. ↵
      1. Chen YW,
      2. Gurol ME,
      3. Rosand J, et al
      . Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology 2006;67:83–7. doi:10.1212/01.wnl.0000223613.57229.24
      OpenUrlCrossRefPubMed
    21. ↵
      1. Gurol ME,
      2. Irizarry MC,
      3. Smith EE, et al
      . Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23–9. doi:10.1212/01.wnl.0000191403.95453.6a
      OpenUrlCrossRefPubMed
    22. ↵
      1. Taylor WD,
      2. Zuchner S,
      3. McQuoid DR, et al
      . The brain-derived neurotrophic factor VAL66MET polymorphism and cerebral white matter hyperintensities in late-life depression. Am J Geriatr Psychiatry 2008;16:263–71. doi:10.1097/JGP.0b013e3181591c30
      OpenUrlCrossRefPubMedWeb of Science
    23. ↵
      1. Hassan A,
      2. Gormley K,
      3. O'Sullivan M, et al
      . Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke 2004;35:654–9. doi:10.1161/01.STR.0000117238.75736.53
      OpenUrlAbstract/FREE Full Text
    24. ↵
      1. Henskens LH,
      2. Kroon AA,
      3. van Boxtel MP, et al
      . Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke 2005;36:1869–73. doi:10.1161/01.STR.0000177867.39769.cb
      OpenUrlAbstract/FREE Full Text
    25. ↵
      1. Kohara K,
      2. Fujisawa M,
      3. Ando F, et al
      . MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the japanese general population: the NILS-LSA study. Stroke 2003;34:1130–5. doi:10.1161/01.STR.0000069163.02611.B0
      OpenUrlAbstract/FREE Full Text
    26. ↵
      1. Linnebank M,
      2. Moskau S,
      3. Jurgens A, et al
      . Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 2009;11:2–8. doi:10.1215/15228517-2008-082
      OpenUrlAbstract/FREE Full Text
    27. ↵
      1. de Lau LM,
      2. van Meurs JB,
      3. Uitterlinden AG, et al
      . Genetic variation in homocysteine metabolism, cognition, and white matter lesions. Neurobiol Aging 2010;31:2020–2. doi:10.1016/j.neurobiolaging.2008.10.004
      OpenUrlCrossRefPubMed
    28. ↵
      1. Pavlovic AM,
      2. Pekmezovic T,
      3. Obrenovic R, et al
      . Increased total homocysteine level is associated with clinical status and severity of white matter changes in symptomatic patients with subcortical small vessel disease. Clin Neurol Neurosurg 2011;113:711–15. doi:10.1016/j.clineuro.2011.07.004
      OpenUrlCrossRefPubMed
    29. ↵
      1. Szolnoki Z,
      2. Somogyvari F,
      3. Kondacs A, et al
      . Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis. Acta Neurol Scand 2004;109:222–7. doi:10.1046/j.1600-0404.2003.00218.x
      OpenUrlCrossRefPubMed
    30. ↵
      1. Szolnoki Z,
      2. Szaniszlo I,
      3. Szekeres M, et al
      . Evaluation of the MTHFR A1298C variant in leukoaraiosis. J Mol Neurosci 2012;46:492–6. doi:10.1007/s12031-011-9621-4
      OpenUrlCrossRefPubMed
    31. ↵
      1. Brenner D,
      2. Labreuche J,
      3. Pico F, et al
      . The renin-angiotensin-aldosterone system in cerebral small vessel disease. J Neurol 2008;255:993–1000. doi:10.1007/s00415-008-0816-8
      OpenUrlCrossRefPubMedWeb of Science
    32. ↵
      1. Verpillat P,
      2. Alperovitch A,
      3. Cambien F, et al
      . Aldosterone synthase (CYP11B2) gene polymorphism and cerebral white matter hyperintensities. Neurology 2001;56:673–5. doi:10.1212/WNL.56.5.673
      OpenUrlCrossRefPubMed
    33. ↵
      1. Amar K,
      2. MacGowan S,
      3. Wilcock G, et al
      . Are genetic factors important in the aetiology of leukoaraiosis? results from a memory clinic population. Int J Geriatr Psychiatry 1998;13:585–90. doi:10.1002/(SICI)1099-1166(199809)13:9<585::AID-GPS825>3.0.CO;2-0
      OpenUrlCrossRefPubMedWeb of Science
    34. ↵
      1. Bracco L,
      2. Piccini C,
      3. Moretti M, et al
      . Alzheimer's disease: role of size and location of white matter changes in determining cognitive deficits. Dement Geriatr Cogn Disord 2005;20:358–66. doi:10.1159/000088562
      OpenUrlCrossRefPubMedWeb of Science
    35. ↵
      1. Dufouil C,
      2. Alperovitch A,
      3. Tzourio C
      . Influence of education on the relationship between white matter lesions and cognition. Neurology 2003;60:831–6. doi:10.1212/01.WNL.0000049456.33231.96
      OpenUrlCrossRefPubMed
    36. ↵
      1. Dufouil C,
      2. Godin O,
      3. Chalmers J, et al
      . Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009;40:2219–21. doi:10.1161/STROKEAHA.108.540633
      OpenUrlAbstract/FREE Full Text
    37. ↵
      1. Hogervorst E,
      2. Ribeiro HM,
      3. Molyneux A, et al
      . Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with alzheimer disease. Arch Neurol 2002;59:787–93. doi:10.1001/archneur.59.5.787
      OpenUrlCrossRefPubMedWeb of Science
    38. ↵
      1. Hong ED,
      2. Taylor WD,
      3. McQuoid DR, et al
      . Influence of the MTHFR C677T polymorphism on magnetic resonance imaging hyperintensity volume and cognition in geriatric depression. Am J Geriatr Psychiatry 2009;17:847–55. doi:10.1097/JGP.0b013e3181aad5b2
      OpenUrlCrossRefPubMed
    39. ↵
      1. Kalman J,
      2. Juhasz A,
      3. Csaszar A, et al
      . Increased apolipoprotein E4 allele frequency is associated with vascular dementia in the hungarian population. Acta Neurol Scand 1998;98:166–8. doi:10.1111/j.1600-0404.1998.tb07288.x
      OpenUrlPubMed
    40. ↵
      1. Kuller LH
      . Risk factors for dementia in the cardiovascular health study cognition study. Rev Neurol 2003;37:122–6.
      OpenUrlPubMed
    41. ↵
      1. Lemmens R,
      2. Gorner A,
      3. Schrooten M, et al
      . Association of apolipoprotein E epsilon2 with white matter disease but not with microbleeds. Stroke 2007;38:1185–8. doi:10.1161/01.STR.0000259816.31370.44
      OpenUrlAbstract/FREE Full Text
    42. ↵
      1. Bartres-Faz D,
      2. Junque C,
      3. Clemente IC, et al
      . MRI and genetic correlates of cognitive function in elders with memory impairment. Neurobiol Aging 2001;22:449–59. doi:10.1016/S0197-4580(01)00207-X
      OpenUrlCrossRefPubMedWeb of Science
    43. ↵
      1. Bornebroek M,
      2. Haan J,
      3. Van Duinen SG, et al
      . Dutch hereditary cerebral amyloid angiopathy: structural lesions and apolipoprotein E genotype. Ann Neurol 1997;41:695–8. doi:10.1002/ana.410410523
      OpenUrlCrossRefPubMedWeb of Science
    44. ↵
      1. Doody RS,
      2. Azher SN,
      3. Haykal HA, et al
      . Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000;69: 668–71. doi:10.1136/jnnp.69.5.668
      OpenUrlAbstract/FREE Full Text
    45. ↵
      1. Carmelli D,
      2. DeCarli C,
      3. Swan GE, et al
      . The joint effect of apolipoprotein E epsilon4 and MRI findings on lower-extremity function and decline in cognitive function. J Gerontol A Biol Sci Med Sci 2000;55:M103–9. doi:10.1093/gerona/55.2.M103
      OpenUrlAbstract/FREE Full Text
    46. ↵
      1. DeCarli C,
      2. Reed T,
      3. Miller BL, et al
      . Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 1999;30:1548–53. doi:10.1161/01.STR.30.8.1548
      OpenUrlAbstract/FREE Full Text
    47. ↵
      1. de Leeuw FE,
      2. Richard F,
      3. de Groot JC, et al
      . Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004;35:1057–60. doi:10.1161/01.STR.0000125859.71051.83
      OpenUrlAbstract/FREE Full Text
    48. ↵
      1. Godin O,
      2. Tzourio C,
      3. Maillard P, et al
      . Apolipoprotein E genotype is related to progression of white matter lesion load. Stroke 2009;40:3186–90. doi:10.1161/STROKEAHA.109.555839
      OpenUrlAbstract/FREE Full Text
    49. ↵
      1. Wen HM,
      2. Baum L,
      3. Cheung WS, et al
      . Apolipoprotein E epsilon4 allele is associated with the volume of white matter changes in patients with lacunar infarcts. Eur J Neurol 2006;13:1216–20. doi:10.1111/j.1468-1331.2006.01436.x
      OpenUrlCrossRefPubMedWeb of Science
    50. ↵
      1. Vuorinen M,
      2. Solomon A,
      3. Rovio S, et al
      . Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study. Dement Geriatr Cogn Disord 2011;31:119–25. doi:10.1159/000323810
      OpenUrlCrossRefPubMed
    51. ↵
      1. Stenset V,
      2. Hofoss D,
      3. Johnsen L, et al
      . White matter lesion load increases the risk of low CSF Abeta42 in apolipoprotein E-varepsilon4 carriers attending a memory clinic. J Neuroimaging 2011;21:e78–82. doi:10.1111/j.1552-6569.2009.00444.x
      OpenUrlCrossRefPubMed
    52. ↵
      1. Smith EE,
      2. Gurol ME,
      3. Eng JA, et al
      . White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004;63:1606–12. doi:10.1212/01.WNL.0000142966.22886.20
      OpenUrlCrossRefPubMed
    53. ↵
      1. Skoog I,
      2. Hesse C,
      3. Aevarsson O, et al
      . A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998;64:37–43. doi:10.1136/jnnp.64.1.37
      OpenUrlAbstract/FREE Full Text
    54. ↵
      1. Schmidt H,
      2. Schmidt R,
      3. Fazekas F, et al
      . Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Clin Genet 1996;50:293–9. doi:10.1111/j.1399-0004.1996.tb02377.x
      OpenUrlPubMedWeb of Science
    55. ↵
      1. Sawada H,
      2. Udaka F,
      3. Izumi Y, et al
      . Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;68:653–6. doi:10.1136/jnnp.68.5.653
      OpenUrlAbstract/FREE Full Text
    56. ↵
      1. Nebes RD,
      2. Vora IJ,
      3. Meltzer CC, et al
      . Relationship of deep white matter hyperintensities and apolipoprotein E genotype to depressive symptoms in older adults without clinical depression. Am J Psychiatry 2001;158:878–84. doi:10.1176/appi.ajp.158.6.878
      OpenUrlCrossRefPubMedWeb of Science
    57. ↵
      1. Benedictus MR,
      2. Goos JD,
      3. Binnewijzend MA, et al
      . Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiol Aging 2013;34:2488–94. doi:10.1016/j.neurobiolaging.2013.04.023
      OpenUrlCrossRefPubMedWeb of Science
    58. ↵
      1. Hirono N,
      2. Yasuda M,
      3. Tanimukai S, et al
      . Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. Stroke 2000;31:1263–8. doi:10.1161/01.STR.31.6.1263
      OpenUrlAbstract/FREE Full Text
    59. ↵
      1. Sleegers K,
      2. den Heijer T,
      3. van Dijk EJ, et al
      . ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala. Neurobiol Aging 2005;26:1153–9. doi:10.1016/j.neurobiolaging.2004.09.011
      OpenUrlCrossRefPubMedWeb of Science
    60. ↵
      1. Sierra C,
      2. Coca A,
      3. Gomez-Angelats E, et al
      . Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. Hypertension 2002;39(2 Pt 2):343–7. doi:10.1161/hy02t2.102912
      OpenUrlCrossRef
    61. ↵
      1. Gormley K,
      2. Bevan S,
      3. Markus HS
      . Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. Cerebrovasc Dis 2007;23:148–55. doi:10.1159/000097052
      OpenUrlCrossRefPubMedWeb of Science
    62. ↵
      1. Hassan A,
      2. Lansbury A,
      3. Catto AJ, et al
      . Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry 2002;72:343–6. doi:10.1136/jnnp.72.3.343
      OpenUrlAbstract/FREE Full Text
    63. ↵
      1. Mizuno T,
      2. Makino M,
      3. Fujiwara Y, et al
      . Renin-angiotensin system gene polymorphism in Japanese stroke patients. International Congress Series 2003;1252:83–90.
      OpenUrlCrossRefWeb of Science
    64. ↵
      1. Schmidt R,
      2. Schmidt H,
      3. Fazekas F, et al
      . Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension 2001;38:110–15. doi:10.1161/01.HYP.38.1.110
      OpenUrlCrossRef
    65. ↵
      1. Hadjigeorgiou GM,
      2. Malizos K,
      3. Dardiotis E, et al
      . Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. J Orthop Res 2007;25:1087–93. doi:10.1002/jor.20393
      OpenUrlCrossRefPubMed
    66. ↵
      1. Schmidt R,
      2. Schmidt H,
      3. Fazekas F, et al
      . MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the austrian stroke prevention study. Arterioscler Thromb Vasc Biol 2000;20:1811–16. doi:10.1161/01.ATV.20.7.1811
      OpenUrlAbstract/FREE Full Text
    67. ↵
      1. Albert MA,
      2. Glynn RJ,
      3. Buring JE, et al
      . Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 2007;99:1246–51. doi:10.1016/j.amjcard.2006.12.041
      OpenUrlCrossRefPubMedWeb of Science
    68. ↵
      1. Anand SS,
      2. Yusuf S,
      3. Vuksan V, et al
      . Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). Lancet 2000;356:279–84. doi:10.1016/S0140-6736(00)02502-2
      OpenUrlCrossRefPubMedWeb of Science
    69. ↵
      1. Carmel R,
      2. Green R,
      3. Jacobsen DW, et al
      . Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr 1999;70:904–10.doi:10.1016/S0140-6736(00)02502-2
      OpenUrlAbstract/FREE Full Text
    70. ↵
      1. Senaratne MP,
      2. Macdonald K,
      3. De Silva D
      . Possible ethnic differences in plasma homocysteine levels associated with coronary artery disease between south asian and east asian immigrants. Clin Cardiol 2001;24:730–4. doi:10.1002/clc.4960241108
      OpenUrlCrossRefPubMed
    71. ↵
      1. Szolnoki Z
      . Pathomechanism of leukoaraiosis. Neuromolecular Med 2007;9:21–33. doi:10.1385/NMM:9:1:21
      OpenUrlCrossRefPubMed
    72. ↵
      1. Smith GD,
      2. Ebrahim S
      . What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 2005;330:1076. doi:10.1136/bmj.330.7499.1076
      OpenUrlFREE Full Text
    73. ↵
      1. Wald DS,
      2. Law M,
      3. Morris JK
      . Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002;325:1202. doi:10.1136/bmj.325.7374.1202
      OpenUrlAbstract/FREE Full Text
    74. ↵
      1. Poirier J,
      2. Bertrand P,
      3. Kogan S, et al
      . Apolipoprotein E polymorphism and Alzheimer's disease. The Lancet 1993;342:697–9. doi:10.1016/0140-6736(93)91705-Q
      OpenUrl
    75. ↵
      1. Rubinsztein DC,
      2. Easton DF
      . Apolipoprotein E genetic variation and Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:199–209. doi:10.1159/000017120
      OpenUrlCrossRefPubMedWeb of Science

    Footnotes

    • Contributors PS conceived the work. TT undertook the primary search. NR undertook the replication. All authors provided data and contributed to the final draft of the manuscript.

    • Funding NH is funded by a MRC (UK) PhD studentship and SY through a British Council/UK-India Education Research Initiative (UKIERI) awarded to PS.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.